Stocks and Investing
Stocks and Investing
Wed, September 16, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, September 15, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joel Beatty Maintained (SRPT) at Strong Buy with Increased Target to $190 on, Sep 15th, 2020
Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $177 to $190 on, Sep 15th, 2020.
Joel has made no other calls on SRPT in the last 4 months.
There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Martin Auster of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $167 on, Thursday, August 20th, 2020
These are the ratings of the 4 analyists that currently disagree with Joel
- Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $221 on, Monday, August 31st, 2020
- Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $200 on, Tuesday, August 25th, 2020
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020